| Master Investor Magazine
|
AIM-listed anti-microbial technology firm Byotrol (LON:BYOT) saw its share price drop by 5.17% to 1.65p (as of 11:45 GMT) despite sales for the six months rising by 93%. Management said that they remained confident in reaching positive EBITDA by the year end as adjusted operating losses narrowed.
Non-executive Chairman John Langlands commented: “We are pleased with progress in the year to date
Trading losses are reducing rapidly and will continue to do so as the formal integration with Medimark concludes at year end. The team is also working on a number of business development and monetisation opportunities that should improve results for the full year. The board remains confident that the Company is on target to deliver sustainable operating profits.
We remain very excited about the business outlook for Byotrol”.